pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,836 catalysts · 5,256 phase readout · 2,333 8k filing · 321 pdufa · 259 earnings · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 0 catalysts2026-07-30: 62 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 13 catalysts2026-08-05: 16 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 1 catalyst2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 1 catalyst2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: phase readout×type: pdufa×type: earnings×clear all
type
  • phase readout5,256
  • 8k filing2,333
  • pdufa321
  • earnings259
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›RECRUITINGphase readoutNCT05534321: Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease

Sponsor: Baptist Health South Florida. Phase: PHASE1. Conditions: Spine Metastases

full page →ctgov ↗
›RECRUITINGphase readoutNCT05902221: Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections

Sponsor: Centre Hospitalier Universitaire de Nice. Phase: PHASE3. Conditions: Infections Joint Prosthetic

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT06335121: Implementation of PrEP Care Among Women in Family Planning Clinics

Sponsor: Rush University Medical Center. Phase: NA. Conditions: PrEP Uptake, HIV, Prevention

full page →ctgov ↗
›RECRUITINGphase readoutNCT02354014: Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB

Sponsor: Janssen Research & Development, LLC. Phase: PHASE2. Conditions: Tuberculosis, Multidrug-Resistant

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07377006: Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

Sponsor: M.D. Anderson Cancer Center. Phase: NA. Conditions: Prostate Carcinoma

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03705806: Palliative Thoracic ImmunoRT

Sponsor: University Health Network, Toronto. Phase: . Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer

full page →ctgov ↗
›COMPLETEDphase readoutNCT05862584: Impact of Air Pollution on the Course of Inflammatory Rheumatism

Sponsor: Centre Hospitalier Universitaire de Nice. Phase: NA. Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06613984: Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

Sponsor: Pfizer. Phase: . Conditions: COVID-19 Vaccination

full page →ctgov ↗
›COMPLETEDphase readoutNCT07167784: Ecological Momentary Assessment and Physical Activity in Patients With Inflammatory Rheumatic Diseases

Sponsor: University Hospital, Grenoble. Phase: . Conditions: Spondyloarthritis (SpA), Rheumatoid Arthritis & Other Inflammatory Polyarthropathies

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT05600933: Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

Sponsor: National Cancer Institute (NCI). Phase: . Conditions: Solid Tumors, Hematologic Malignancy, Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma, Pre-Malignancy, Lung Cancer

full page →ctgov ↗
›COMPLETEDphase readoutNCT01413152: Residual Risk Assessment Of HIV Transmission

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis. Phase: NA. Conditions: HIV Infection

full page →ctgov ↗
›COMPLETEDphase readoutNCT06401733: Intensive Aerobic and Resistance Exercise Program (IAREP)

Sponsor: National University of Singapore. Phase: NA. Conditions: Type 2 Diabetes Mellitus, Cognitive Impairment, Non-insulin-dependent Diabetes Mellitus, Cognitive Dysfunction

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT06959433: Lu-177 PSMA Treatment in Cell Renal Carcinoma

Sponsor: Ankara University. Phase: PHASE3. Conditions: Metastatic Renal Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT06944652: Stretching to Improve Jumping Performance

Sponsor: University of Saskatchewan. Phase: NA. Conditions: Vertical Jump Performance

full page →ctgov ↗
›RECRUITINGphase readoutNCT06384352: Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.. Phase: PHASE1. Conditions: Advanced Solid Tumors

full page →ctgov ↗
›COMPLETEDphase readoutNCT07655947: Theory of Planned Behavior-Based Digital Addiction and Screen Time Management Training for Teachers

Sponsor: Aydin Adnan Menderes University. Phase: NA. Conditions: Digital Addiction and Screen Time Management Among Teachers

full page →ctgov ↗
›RECRUITINGphase readoutNCT07295847: A Study of AZD0120 in Autoimmune Diseases

Sponsor: AstraZeneca. Phase: PHASE1. Conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis

full page →ctgov ↗
›RECRUITINGphase readoutNCT07603947: Impact of Forward Head Posture on Postural Stability and Gait Kinematics

Sponsor: Cairo University. Phase: . Conditions: Forward Head Posture, Postural Stability, Gait Analysis

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT07371247: Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy

Sponsor: The First Affiliated Hospital with Nanjing Medical University. Phase: EARLY_PHASE1. Conditions: Esophageal Cancer, MRD, ctDNA

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT01815749: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Sponsor: City of Hope Medical Center. Phase: PHASE1. Conditions: Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia

full page →ctgov ↗
›COMPLETEDphase readoutNCT03892148: Protocol of Diuretics Use in Congestive Therapy in Heart Failure

Sponsor: University Hospital, Clermont-Ferrand. Phase: PHASE4. Conditions: Heart Failure, Acute Heart Failure, Chronic Heart Failure

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07327255: Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia

Sponsor: Evergreen Therapeutics, Inc.. Phase: PHASE1. Conditions: Pre-eclampsia

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03642626: MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Sponsor: Masonic Cancer Center, University of Minnesota. Phase: PHASE2. Conditions: Acute Lymphoblastic Leukemia, Large B-cell Lymphoma

full page →ctgov ↗
›COMPLETEDphase readoutNCT07506278: Results Of Vivifrail Exercise In Older Type 2 Diabetic Patients With Fraity Syndrome

Sponsor: National Geriatric Hospital. Phase: NA. Conditions: Type 2 Diabetes, Fraity Syndrome, Exercise Intervention

full page →ctgov ↗
›RECRUITINGphase readoutNCT07368478: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

Sponsor: Biocity Biopharmaceutics Co., Ltd.. Phase: PHASE1. Conditions: Advanced Solid Malignancies

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06869785: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Sponsor: Novartis Pharmaceuticals. Phase: PHASE3. Conditions: Relapsing Multiple Sclerosis (RMS)

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07540585: MOCHA: Embedded Inpatient Mental Health Care for High-Risk Perinatal Patients

Sponsor: Indiana University. Phase: . Conditions: Anxiety Disorders, Stress Disorders, Post-Traumatic, Pregnancy, High Risk, Depressive Disorder, Major, Pregnancy Complications, ADHD - Attention Deficit Disorder With Hyperactivity

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03979885: Financial Incentives for Smoking Treatment II

Sponsor: University of California, Los Angeles. Phase: NA. Conditions: Smoking Cessation, Tobacco Use Cessation

full page →ctgov ↗
›RECRUITINGphase readoutNCT05813678: A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)

Sponsor: BioMarin Pharmaceutical. Phase: . Conditions: Phenylketonuria (PKU)

full page →ctgov ↗
›COMPLETEDphase readoutNCT00720785: Natural Killer Cells and Bortezomib to Treat Cancer

Sponsor: National Heart, Lung, and Blood Institute (NHLBI). Phase: PHASE1. Conditions: Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung

full page →ctgov ↗
›COMPLETEDphase readoutNCT04397185: Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer

Sponsor: CairnSurgical, Inc.. Phase: NA. Conditions: Breast Cancer Female

full page →ctgov ↗
›RECRUITINGphase readoutNCT06834685: Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy in Cancer Patients

Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle. Phase: NA. Conditions: Cancer Survivors, Peripheral Neuropathic Pain

full page →ctgov ↗
›COMPLETEDphase readoutNCT07416643: The Role of Incorporating Acacia Gum in Foods on Glucose Homeostasis in Healthy Humans

Sponsor: King Abdulaziz University. Phase: NA. Conditions: Health Adult Subjects

full page →ctgov ↗
›COMPLETEDphase readoutNCT04684615: Mental Health Impact of the COVID-19 Pandemic on Amish and Mennonite Participants in AMBiGen

Sponsor: National Institute of Mental Health (NIMH). Phase: . Conditions: Depression, Anxiety, Bipolar Disorder

full page →ctgov ↗
›COMPLETEDphase readoutNCT07263698: Investigation of Clinical Efficacy of a New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems as Compared to a Control Mouthwash

Sponsor: Colgate Palmolive. Phase: PHASE3. Conditions: Gingivitis, Plaque, Dental

full page →ctgov ↗
›RECRUITINGphase readoutNCT06800898: Orexin Gene in Anorexia Nervosa

Sponsor: Istituto Auxologico Italiano. Phase: . Conditions: Anorexia Nervosa

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07634263: Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study

Sponsor: Odense University Hospital. Phase: . Conditions: Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression, Multiple Myeloma Refractory

full page →ctgov ↗
›RECRUITINGphase readoutNCT06700187: Frequency of Interrupting Sitting and Cognitive Function

Sponsor: Maastricht University Medical Center. Phase: NA. Conditions: Sedentary Behaviors, Breaking Prolonged Sitting With Physical Activity

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT07386587: Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis

Sponsor: University of Child Health Sciences and Children's Hospital, Lahore. Phase: PHASE3. Conditions: Juvenile Idiopathic Arthritis

full page →ctgov ↗
›RECRUITINGphase readoutNCT07315087: CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Sponsor: Institute of Hematology & Blood Diseases Hospital, China. Phase: PHASE1. Conditions: SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies, ANCA Associated Vasculitis (AAV), Connective Tissue Disease-Associated Thrombocytopenia, SLE-ITP

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07600463: UVC in Prevention of Surgical Wound Infection

Sponsor: Ville Leinonen. Phase: NA. Conditions: Hydrocephalus

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT02777593: Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2

Sponsor: W.L.Gore & Associates. Phase: NA. Conditions: Aortic Aneurysm, Thoracic, Aorta; Lesion

full page →ctgov ↗
›RECRUITINGphase readoutNCT05583721: Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

Sponsor: St. Jude Children's Research Hospital. Phase: PHASE2. Conditions: Sickle Cell Disease

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07646314: Comparative Effects of Post-Isometric Relaxation and Reciprocal Inhibition Techniques inPiriformis Syndrome

Sponsor: Riphah International University. Phase: NA. Conditions: Piriformis Syndrome

full page →ctgov ↗
›COMPLETEDphase readoutNCT06308614: Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

Sponsor: Estetra. Phase: PHASE2. Conditions: Sexual Dysfunction, Physiological

full page →ctgov ↗
›RECRUITINGphase readoutNCT05145816: Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Sponsor: University of Texas Southwestern Medical Center. Phase: PHASE1. Conditions: AL Amyloidosis, Amyloidosis

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT04996316: MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals

Sponsor: OHSU Knight Cancer Institute. Phase: . Conditions: Breast Carcinoma

full page →ctgov ↗
›COMPLETEDphase readoutNCT05709106: A Prospective Real World Study of Rimegepant in the Treatment of Migraine

Sponsor: Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine. Phase: . Conditions: Migraine

full page →ctgov ↗
›RECRUITINGphase readoutNCT05085704: Brain Metabolism Observed at 3 Tesla or 7 Tesla in Health and Metabolic Disease

Sponsor: Weill Medical College of Cornell University. Phase: . Conditions: Glut1 Deficiency Syndrome 1, Glucose Metabolism Disorders, Epilepsy, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter Protein Type 1 Deficiency Syndrome, Glucose Transport Defect

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07492433: Risk Factors, Incidence, and Clinical Impact of Intraluminal Thrombosis Following FET and TEVAR

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Phase: . Conditions: Intraluminal Thrombosis, Tevar, FET

full page →ctgov ↗
← prev
page 103 of 117
next →